PHARMA MAR, S.A. «...1112131415...» Page 13 out of 23 22/02/2022 17:19 PHARMA MAR, S.A. Other relevant information The Company reports that will host a key opinion leader (KOL) webinar on Small Cell Lung Cancer (SCLC) on March 9th, 2022, at 19.00 CET Register number: 14177 11/01/2022 08:29 PHARMA MAR, S.A. Other relevant information The Company reports that the publication titled “Pre-clinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19” has been published in the Life Science Alliance journal. Register number: 13557 05/01/2022 11:44 PHARMA MAR, S.A. Liquidity and counterparty agreements The Company reports details of the operations of the Liquidity Agreement between 01/10/2021 and 31/12/2021 Register number: 13523 22/12/2021 08:28 PHARMA MAR, S.A. On business and financial situation The Company announces the signature of a license and commercialization agreement with Eczacibasi Pharmaceuticals Marketing Co. to commercialize the anticancer drug lurbinectedin in Turkey. Register number: 13305 13/12/2021 08:26 PHARMA MAR, S.A. On business and financial situation The Company announces the initiation of a confirmatory Phase III clinical trial, LAGOON, evaluating Zepzelca® (lurbinectedin) for the treatment of patients with relapsed Small Cell Lung Cancer (SCLC). Register number: 13128 11/11/2021 08:26 PHARMA MAR, S.A. On business and financial situation The Company announces the signature of a license agreement with Lotus Pharmaceutical CO., Ltd. to commercialize lurbinectedin in Taiwan. Register number: 12698 02/11/2021 08:28 PHARMA MAR, S.A. On business and financial situation Pharma Mar’s statement Register number: 12516 28/10/2021 17:36 PHARMA MAR, S.A. Other relevant information - On business and financial situation The Company files third quarter 2021 financial information and announces a conference call with analysts and investors. Register number: 12437 06/10/2021 17:42 PHARMA MAR, S.A. Liquidity and counterparty agreements The Company reports details of the operations of the Liquidity Agreement between 13/07/2021 and 30/09/2021 Register number: 12093 30/09/2021 08:15 PHARMA MAR, S.A. On business and financial situation The Company announces the approval of Zepzelca (lurbinectedin) for the treatment of relapsed stage III or metastatic Small Cell Lung Cancer in Canada. Register number: 11918 Page 13 out of 23 «...1112131415...»
